GlassScriptPhysician profile
Barry S Taney
NPI 1538167705
$6,416.16
in general payments reported to CMS, 2019-2025
21 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $32.52 · 2021: $458 · 2022: $888 · 2023: $1,557 · 2024: $1,173 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,265.93 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,515.45 | 2019-2024 | Vabysmo, Lunsumio, Lucentis |
| Apellis Pharmaceuticals, INC. | $617.41 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $258.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $258.33 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $247.49 | 2021-2023 | Tecnis Iol |
| Astellas Pharma US INC | $205.45 | 2024-2025 | Izervay |
| Allergan, INC. | $158.81 | 2019 | |
| Bausch & Lomb Americas INC. | $125.00 | 2024 | Vyzulta |
| Kala Pharmaceuticals, INC. | $122.07 | 2019 | |
| Harrow Eye, LLC | $115.77 | 2024 | Iheezo |
| Eyevance Pharmaceuticals LLC | $106.76 | 2021 | |
| Sandoz INC. | $99.89 | 2024-2025 | Cimerli |
| Ani Pharmaceuticals, INC. | $91.88 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Coherus Oncology, INC. | $71.54 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.26 | 2019-2021 | |
| Abbvie INC. | $33.80 | 2025 | |
| Lumibird Medical INC. | $22.72 | 2025 | |
| Notal Vision, INC. | $21.42 | 2024 | Foresee Home |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Viiv Healthcare Company | $16.06 | 2023 | Cabenuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Taney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.